KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBITDA Margin (2019 - 2025)

Esperion Therapeutics' EBITDA Margin history spans 7 years, with the latest figure at 36.71% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 6755.0% year-over-year to 36.71%; the TTM value through Dec 2025 reached 5.63%, up 994.0%, while the annual FY2025 figure was 5.63%, 994.0% up from the prior year.
  • EBITDA Margin reached 36.71% in Q4 2025 per ESPR's latest filing, up from 35.89% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 44.3% in Q1 2024 to a low of 1139.82% in Q1 2021.
  • Average EBITDA Margin over 5 years is 216.9%, with a median of 148.07% recorded in 2023.
  • Peak YoY movement for EBITDA Margin: surged 311360bps in 2021, then plummeted -24480bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 423.02% in 2021, then surged by 30bps to 294.38% in 2022, then skyrocketed by 41bps to 174.71% in 2023, then skyrocketed by 82bps to 30.85% in 2024, then soared by 219bps to 36.71% in 2025.
  • Per Business Quant, the three most recent readings for ESPR's EBITDA Margin are 36.71% (Q4 2025), 35.89% (Q3 2025), and 15.45% (Q2 2025).